Kinfo
Palatin Technologies Inc. logo

Palatin Technologies Inc.

PTNNYSEHealthcare·US · USD
$6.23
-0.34 (-5.18%)
Prices as of November 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap11.10M USD
Enterprise value4.43M USD
Trailing P/E91.20
Forward P/E-4.51
PEG ratio-0.95
Price / sales0.83
Price / book1.64
Profitability
Gross margin0.00%
Operating margin-65.74%
Profit margin-63.54%
Return on assets-91.90%
Return on equity-877.53%
Income (TTM)
Revenue13.19M USD
Gross profit816.16K USD
EBITDA-8.61M USD
Net income-8.38M USD
Diluted EPS-$2.96
Rev. growth (YoY)3278.84%
Balance sheet
Total cash7.49M USD
Total debt223.68K USD
Debt / equity3.35
Current ratio4.61
Book value / share$3.76
Cash flow (TTM)
Operating cash flow-13.53M USD
Levered free cash flow-10.67M USD
Shares & price
Shares outstanding1.78M
Float1.56M
Held by institutions51.93%
Beta0.32
50-day MA$8.34
200-day MA$13.57
52-week high$31.00
52-week low$4.51
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-09-28-1.12-1.11+0.89%2026-07-271.541.69+9.74%2026-05-13-0.82-0.37+54.88%2026-04-293.694.10+11.11%2026-02-17-1.47-2.86−94.56%
About Palatin Technologies Inc.

Palatin Technologies Inc. is a biopharmaceutical company focused on developing first-in-class medicines that act on the melanocortin receptor system. Its current portfolio centers on receptor-targeted therapeutics for obesity, rare neuroendocrine disorders, inflammatory conditions, autoimmune diseases, and ocular disorders. The company’s work includes product candidates and partnered programs designed to address areas with significant unmet medical need, with a focus on selective peptide and small-molecule approaches. Palatin Technologies also participates in collaboration and licensing activities that support its research and development efforts across multiple therapeutic areas. Based in Princeton, New Jersey, Palatin Technologies Inc. operates as a clinical-stage company within the healthcare sector, where it contributes to the development of novel treatments aimed at specialized patient populations.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Carl Spana Ph.D.
Employees
25
Headquarters
Princeton, NJ, United States

Frequently asked questions about Palatin Technologies Inc.